Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | P4HA1 | P13674 | 2/20 | 0.33 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL669121 | 0.77 | NNMT (0.52) | SMN1; SMN2SMYD3KDM4EHSD17B10POLB | |
| SCHEMBL14782157 | 0.77 | NAPRT (0.41) | NAPRTRAB9ASMN1; SMN2HDAC1HDAC6 | |
| SCHEMBL2175856 | 0.77 | KCNJ1 (0.39) | RAB9ASMN1; SMN2HDAC1HDAC6SMYD3 | |
| SCHEMBL185619 | 0.77 | ALDH1A1 (0.58) | NAPRTSMN1; SMN2ALDH1A1KDM4EALOX15 | |
| SCHEMBL6987829 | 0.77 | NAPRT (0.46) | NAPRTRAB9ASMN1; SMN2DGAT1P4HA1 | |
| SCHEMBL20396058 | 0.75 | NAPRT (0.40) | NAPRTSMN1; SMN2HDAC1HDAC6ALDH1A1 | |
| SCHEMBL31497513 | 0.75 | HDAC1 (0.56) | NAPRTSMN1; SMN2HDAC1HDAC6ALDH1A1 | |
| SCHEMBL1435924 | 0.75 | NAPRT (0.36) | NAPRTRAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL4274472 | 0.75 | MAPK1 (0.37) | NAPRTRAB9ASMN1; SMN2HDAC1HDAC6 | |
| SCHEMBL600144 | 0.75 | HDAC1 (0.60) | NAPRTRAB9ASMN1; SMN2HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107683283-B | BACE1 inhibitors | 豪夫迈·罗氏有限公司 | 2021-05-18 | — | — | CN | disclosed |
| US-10696691-B2 | BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190270757-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-09-05 | — | — | US | disclosed |
| EP-3334742-B1 | BACE1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-05-08 | — | — | EP | disclosed |
| US-10246468-B2 | BACE1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2019-04-02 | — | — | US | disclosed |
| US-20190002476-A1 | BACE1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2019-01-03 | — | — | US | disclosed |
| EP-3334742-A1 | BACE1 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2018-06-20 | — | — | EP | disclosed |
| CN-107683283-A | Bace1 inhibitor | 豪夫迈·罗氏有限公司 | 2018-02-09 | — | — | CN | disclosed |
| WO-2017025491-A1 | BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-02-16 | — | — | WO | disclosed |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| CN-101018770-A | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARM INC (US) | 2007-08-15 | — | — | CN | disclosed |
| EP-1740547-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005100321-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | NAPRT 1973/4885RAB9A 2883/4885SMN1; SMN2 4770/4885 |
| US-10696691-B2 | BACE1 inhibitors | BACE1, BACE2, APP | NAPRT 986/4885RAB9A 1581/4885SMN1; SMN2 936/4885 |
| US-10246468-B2 | BACE1 inhibitors | BACE1, BACE2, APP | NAPRT 1026/4885RAB9A 1570/4885SMN1; SMN2 997/4885 |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | NAPRT 1973/4885RAB9A 2883/4885SMN1; SMN2 4770/4885 |
| US-20190270757-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | NAPRT 986/4885RAB9A 1581/4885SMN1; SMN2 936/4885 |
| US-20190002476-A1 | BACE1 INHIBITORS | BACE1, BACE2, APP | NAPRT 986/4885RAB9A 1581/4885SMN1; SMN2 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.